

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
National Pharmaceutical Pricing Authority

New Delhi, the 24<sup>th</sup> May, 2017

**ORDER**

**SO. 1689(E)** In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30<sup>th</sup> May, 2013 and S. O. 701(E) dated 10<sup>th</sup> March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Telmisartan + Metoprolol ER Tablet (Telmijub Beta 25)	Each film coated bilayered tablet contains: Telmisartan 40mg Metoprolol succinate eq. to Metoprolol Tartrate 25mg (as extended release)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Jubilant Life Sciences Limited	7.95
2.	Telmisartan + Metoprolol ER Tablet (Telmijub Beta 50)	Each film coated bilayered tablet contains: Telmisartan 40mg Metoprolol succinate eq. to Metoprolol Tartrate 50mg (as extended release)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Jubilant Life Sciences Limited	9.55
3.	Glimepiride + Voglibose + Metformin SR Tablet	Each uncoated bilayered tablet contains: Glimepiride 1mg Voglibose 0.2mg Metformin HCL 500mg	10 Tablets	M/s Windlas Biotech Ltd./M/s Glenmark Pharmaceuticals Ltd.	71.43

		(as sustained released form)			
4.	Glimepiride + Voglibose + Metformin SR Tablet	Each uncoated bilayered tablet contains: Glimepiride 2mg Voglibose 0.2mg Metformin HCL 500mg (as sustained released form)	10 Tablets	M/s Windlas Biotech Ltd./M/s Glenmark Pharmaceuticals Ltd.	90.48
5.	Telmisartan + Chlorthalidone Tablet (Telpres CT 80)	Each uncoated bilayered tablet contains: Telmisartan 80mg Chlorthalidone 12.5mg	1 Tablet	M/s Windlas Biotech Ltd./M/s Abbott Healthcare Pvt. Ltd.	7.00
6.	Diclofenac Diethylamine + Linseed Oil + Methyl Salicylate + Menthol Gel ( DICLOTAL+ Gel)	Each gm contains: Diclofenac Diethylamine 1.16% w/w (eq. to diclofenac Sodium 1% w/w) Linseed Oil 3% w/w Methyl Salicylate 10% w/w Menthol 5% w/w	1 GM	M/s The Madras Pharmaceuticals /M/s Blue Cross Lab. Pvt. Ltd.	2.15
7.	Rozuplatt 10 Capsules	Each hard gelatine capsule contains: Rosuvastatin calcium eq. to Rosuvastatin 10mg (As pellets) Clopidogrel Bisulphate eq. to Clopidogrel 75mg (As pellets)	1 Capsule	M/s Torrent Pharmaceuticals Ltd.,/ M/s Synokem Pharmaceuticals Ltd.	13.94

Note:

- (a) The manufacturers of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

- (e) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/177/45/2017/F

F. No. 8(45)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director